GNI Group Ltd. (FRA:3G6)

Germany flag Germany · Delayed Price · Currency is EUR
17.10
+0.90 (5.56%)
At close: Mar 27, 2026
Market Cap980.92M -8.5%
Revenue (ttm)145.80M +13.7%
Net Income-23.96M
EPS-0.46
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume138
Open17.10
Previous Close16.20
Day's Range17.10 - 17.10
52-Week Range8.80 - 26.00
Betan/a
RSI54.87
Earnings DateMay 15, 2026

About GNI Group

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue-associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, the company is involved i... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2001
Employees 867
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 3G6

Financial Performance

Financial numbers in JPY Financial Statements